Abstract
Crohn’s disease (CD) is a chronic inflammation of the digestive tract that significantly impairs patients’ quality of life and well-being. Anti-TNF biologicals revolutionised the treatment of CD,yet many patients do not adequately respond to such therapy. Previous studies have demonstrated apro-inflammatory pattern in the composition of CD patients’ immunoglobulin G (IgG) N-glycomecompared to healthy individuals. Here, we utilised the high-throughput UHPLC method for N-glycan analysis to explore the longitudinal effect of the anti-TNF drugs infliximab and adalimumabon N-glycome composition of total serum IgG in 198 patients, as well as the predictive potential ofIgG N-glycans at baseline to detect primary non-responders to anti-TNF therapy in 1315 patients. Wediscovered a significant decrease in IgG agalactosylation and an increase in monogalactosylation,digalactosylation and sialylation during the 14 weeks of anti-TNF treatment, regardless of therapyresponse, all of which suggested a diminished inflammatory environment in CD patients treated withanti-TNF therapy. Furthermore, we observed that IgG N-glycome might contain certain informationregarding the anti-TNF therapy outcome before initiating the treatment. However, it is impossible to predict future primary non-responders to anti-TNF therapy based solely on IgG N-glycomecomposition at baseline.
Original language | English |
---|---|
Article number | 954 |
Number of pages | 13 |
Journal | Biomolecules |
Volume | 13 |
Issue number | 6 |
DOIs | |
Publication status | Published - 7 Jun 2023 |
Keywords
- Crohn’s disease
- IgG glycosylation
- infliximab
- adalimumab
- PANTS study